Moving up the value chain into higher-margin systems
At the opening of June 2026, a leading Indian brokerage placed its conviction behind two companies navigating the quieter but consequential currents of national defense and global healthcare — industries where patient capital and structural demand tend to reward those who arrive early. Motilal Oswal's dual recommendation of Astra Microwave and Shaily Engineering Plastics reflects a broader truth about this moment in India's economic story: that growth is being seeded not in speculation, but in the unglamorous work of building radar systems and precision plastic pens. Both stocks carry identical upside targets, yet their journeys run through entirely different human needs — the desire for security and the desire for health.
- Astra Microwave closed FY26 with inflows surging 29% year-over-year, powered by India's accelerating defense modernization across radar, air defense, and electronic warfare programs.
- Shaily Engineering faces a rare convergence of tailwinds as semaglutide patent expirations flood emerging markets with demand for the precision insulin and GLP-1 delivery pens it has spent decades learning to make.
- Shaily has locked in sole-supplier agreements with major healthcare clients and is racing to expand pen manufacturing capacity fivefold — from current levels to over 150 million units annually by FY28.
- Astra's ambitions stretch further still, with management targeting a near-tripling of revenue by FY30-31 as strategic defense contracts move from order book to execution.
- Both stocks are rated buy with 14% upside targets, grounded in visible order pipelines and committed customer relationships rather than speculative demand forecasts.
On the first trading day of June 2026, Motilal Oswal's research team issued buy recommendations on two companies — Astra Microwave and Shaily Engineering Plastics — each carrying a 14 percent upside target and each riding a distinct but durable growth wave.
Astra Microwave had just closed a strong fiscal year, booking 16.6 billion rupees in inflows — a 29 percent jump over the prior year. Its order book maps directly onto India's defense modernization agenda: Uttam radar systems, the QRSAM air defense program, Su-30 upgrades, electronic warfare platforms, and strategic space initiatives. Management guided for 13 to 14 billion rupees in FY27 revenue, implying 15 to 20 percent growth, while the longer horizon pointed toward nearly tripling revenue by FY30-31. Analysts revised their estimates upward, projecting revenue, EBITDA, and profit to compound at 20, 17, and 30 percent respectively through FY28.
Shaily Engineering Plastics brought a different story. After nearly four decades supplying precision plastic components to multinationals — IKEA, Unilever, Gillette, GE, and others — the company found itself at the center of a healthcare inflection point. The expiration of semaglutide patents in emerging markets has unleashed demand for GLP-1 and insulin delivery pens, exactly the kind of high-precision components Shaily manufactures. With sole-supplier agreements secured, the company committed to expanding pen capacity fivefold, targeting over 150 million units annually by FY28. Analysts projected revenue, EBITDA, and profit growing at 29, 38, and 43 percent compound rates through FY28, with EBITDA margins holding above 32 percent.
What united both recommendations was the quality of their foundations — concrete order visibility and committed customer relationships, not conjecture. Astra's trajectory depends on India's sustained defense investment; Shaily's on the global proliferation of obesity and diabetes treatments. Neither thesis rests on fragile assumptions, and for investors seeking sector-specific exposure at the start of a promising fiscal year, both offered considered entry points.
On the first trading day of June 2026, Motilal Oswal's research team issued a straightforward recommendation: buy Astra Microwave and Shaily Engineering Plastics. Both stocks carried the same target—a 14 percent upside from their current prices. The recommendation arrived not as a dramatic call but as a measured assessment of two companies moving through distinct but equally compelling growth cycles.
Astra Microwave had just closed out its fiscal year with results that exceeded expectations. The company pulled in 16.6 billion rupees in inflows during FY26, a jump of 29 percent year-over-year. The gains came from tighter margins and strengthening export momentum, particularly in the final quarter when demand for higher-value RF systems and SDR-related equipment picked up. The company's order book reads like a map of India's defense modernization: Uttam radar systems, the QRSAM air defense program, Su-30 fighter jet upgrades, electronic warfare systems, weather radars, and strategic space initiatives. For the year ahead, management targeted revenue between 13 and 14 billion rupees, implying growth of 15 to 20 percent. The longer view was more ambitious. Astra aimed to nearly triple its revenue by fiscal 2030-31, banking on the execution of these strategic defense programs, improving operational leverage, and stronger cash generation. The research desk upgraded its estimates for the next two years, projecting revenue, EBITDA, and profit to expand at a compound annual rate of 20, 17, and 30 percent respectively through FY28.
Shaily Engineering Plastics occupied a different corner of the market but faced equally tailwinds. The company had spent nearly four decades perfecting precision plastic manufacturing, serving multinational giants across healthcare, consumer goods, personal care, appliances, automotive, and lighting. Its customer roster included IKEA, Unilever, Gillette, Procter & Gamble, General Electric, and Garrett. What had shifted recently was demand in healthcare. The expiration of semaglutide patents in emerging markets had unlocked demand for GLP-1 and insulin delivery pens—devices that require the exact kind of precision plastic components Shaily manufactures. The company had secured sole-supplier agreements with major healthcare customers and committed to a fivefold expansion of its pen manufacturing capacity, aiming to produce over 150 million units annually by FY28. The research team expected this momentum to sustain, projecting revenue, EBITDA, and profit to grow at compound annual rates of 29, 38, and 43 percent respectively through FY28. EBITDA margins were expected to hold above 32 percent, while return on equity and return on capital employed would expand to roughly 28 and 36 percent by FY28.
Both recommendations rested on concrete order visibility and customer commitments rather than speculation about future demand. Astra's growth depended on the Indian government's willingness to fund defense modernization—a reasonable bet given geopolitical tensions and stated policy priorities. Shaily's growth hinged on the global pharmaceutical industry's need for injection devices as obesity and diabetes treatments proliferated. Neither story was fragile. The research desk had assigned both stocks a buy rating and set identical 14 percent upside targets, though the paths to those gains ran through very different industries and geographies. For investors with a medium-term horizon and appetite for sector-specific exposure, both offered entry points at the start of what the analysts expected to be a strong fiscal year.
Notable Quotes
Astra aims to nearly triple revenue by FY30-31, backed by strategic defense programs and improving operating leverage.— Motilal Oswal Research Desk
Shaily's healthcare business is witnessing strong momentum from rising GLP-1 and insulin pen demand after semaglutide patent expiries in emerging markets.— Motilal Oswal Research Desk
The Hearth Conversation Another angle on the story
Why does Astra Microwave matter right now? It's a defense contractor—aren't those always cyclical?
Astra's different because India is in the middle of a genuine modernization cycle. The Uttam radar, QRSAM, Su-30 upgrades—these aren't one-off orders. They're multi-year programs with committed budgets. The company just proved it can execute and improve margins while doing it.
And the 29 percent inflow growth—is that sustainable?
That's the question. But they're not projecting that rate to continue. They're guiding for 15 to 20 percent growth next year, which is more conservative. The real story is that they're moving up the value chain—higher-margin RF systems instead of commodity components.
What about Shaily? A plastics company seems less exciting than defense.
On the surface, yes. But Shaily is positioned at the intersection of two massive trends: obesity drug adoption and the shift to injectable delivery. They're not competing on price. They have sole-supplier agreements. That's a different kind of moat.
The capacity expansion to 150 million units—can they actually pull that off?
They have customer commitments backing it. That's not Shaily betting on demand. That's customers telling them how much they need. The risk is execution, not demand.
Both stocks show 14 percent upside. Is that conservative?
For a six-to-twelve month horizon, yes, probably. But these are research recommendations, not price targets. The real upside comes if either company executes better than expected. The 14 percent is the floor, not the ceiling.
So what's the catch?
Astra depends on government spending and geopolitical stability. Shaily depends on pharmaceutical companies maintaining their investment in obesity drugs. Neither is guaranteed. But both have visibility into their order books that most companies don't have.